Skip to content


Lifesaving diagnostic solutions for everyone

About BioMedomics

Founded in 2007 and headquartered in RTP, North Carolina, BioMedomics is a privately-held, commercial-stage biotech and point-of-care diagnostic company.
Driven by a passion for innovation, BioMedomics has invested over $25 million in R&D and manufacturing, boasting a robust intellectual property portfolio with 15 core patents and 13 additional applications pending. The state-of-the-art research center spans 15,000 square feet, housing an ISO 13485-compliant manufacturing area equipped with cutting-edge instruments. But the greatest asset is the team: a group of highly talented individuals dedicated to R&D, manufacturing, quality systems, regulatory approvals, finance, sales, and marketing.
BioMedomics’ commitment to innovation is evident as follows:
-World’s leading manufacturer of hemoglobin S and hemoglobin F;
-World’s first rapid, POCT (point of care testing) Sickle SCAN ® for SCD (sickle cell disease) and trait;
-Global reach: Sickle SCAN ® and other products sold in over 40 countries with a worldwide network of distribution partners.

Our Vision

We create lifesaving diagnostic technologies for everyone, even those living in the remotest and most under-resourced regions of the world.

Our Commitment

We are committed to saving and improving lives by making cutting edge diagnostic technologies globally accessible and affordable. Our researchers combine biology, biochemistry, and biomedical engineering to merge advanced technologies with novel point-of-care diagnostic platforms. Every product we make offers the same clinical accuracy as standard tests performed in central lab settings, only at a significantly lower cost — no specialized lab equipment required.